



**Miltenyi Biotec**

## Reference list

# CliniMACS Prodigy® T Cell Transduction

## Clinical study results – patient treatment with CAR T cell products

Foy, S. *et al.* (2023) Non-viral precision T cell receptor replacement for personalized cell therapy. *Nature*. 615(7953): 687–696  
<https://doi.org/10.1038/s41586-022-05531-1>

Kerkre, N. *et al.* (2022) CLIC-01: Manufacture and distribution of non-cryopreserved CAR-T cells for patients with CD19 positive hematologic malignancies. *Front. Immunol.* 13: 1074740  
<https://doi.org/10.3389/fimmu.2022.1074740>

Mackensen, A. *et al.* (2021) Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. *Nature Med.* 28: 2124–2132  
<https://doi.org/10.1038/s41591-022-02017-5>

Maschan, M. *et al.* (2021) Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients. *Nat. commun.* 12: 7200.  
<https://doi.org/10.1038/s41467-021-27312-6>

Mougiakakos, D. *et al.* (2021) CD19-targeted CAR T cells in refractory systemic lupus erythematosus. *N. Engl. J. Med.* 385: 567–569.  
<https://www.doi.org/10.1056/NEJMc2107725>

Ortiz-Maldonado, V. *et al.* (2021) CART19-BE-01: A multicenter trial of ARI-0001 cell therapy in patients with CD19<sup>+</sup> relapsed/refractory malignancies. *Mol. Ther.* 29: 636–644.  
<https://doi.org/10.1016/j.jymthe.2020.09.027>

Castella, M. *et al.* (2020) Point-of-care CAR T-cell production (ARI-0001) using a closed semi-automatic bioreactor: Experience from an academic phase I clinical trial. *Front. Immunol.* 11: 482.  
<https://doi.org/10.3389/fimmu.2020.00482>

Jackson, Z. *et al.* (2020) Automated manufacture of autologous CD19 CAR-T cells for treatment of non-hodgkin lymphoma. *Front. Immunol.* 11: 1941.  
<https://doi.org/10.3389/fimmu.2020.01941>

Shah, N. N. *et al.* (2020) Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: A phase 1 dose escalation and expansion trial. *Nat. Med.* 26: 1569–1575.  
<https://doi.org/10.1038/s41591-020-1081-3>

## Technical performance – manufacturing feasibility, CAR T cell functionality, and pre-clinical data

Nicod, C. *et al.* (2023) CAR-T cells targeting IL-1RAP produced in a closed semiautomatic system are ready for the first phase I clinical investigation in humans. *Curr. Res. Transl. Med.* 71:103385  
<https://doi.org/10.1016/j.retram.2023.103385>

Palani, H. K. *et al.* (2023) Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy®: real-world experience and cost analysis in India. 58: 160–167  
<http://doi:10.1038/s41409-022-01866-5>

Glienke, W. *et al.* (2022) GMP-compliant manufacturing of TRUCKs: CAR T cells targeting GD2 and releasing inducible IL-18. *Front. Immunol.* 13: 839783  
<https://doi.org/10.3389/fimmu.2022.839783>

Joedicke, J. *et al.* (2022) Accelerating clinical-scale production of BCMA CAR T cells with defined maturation stages. *Mol. Thera. Methods Clin. Dev.* 24: 181–198.  
<https://doi.org/10.1016/j.omtm.2021.12.005>

Majzner, R. *et al.* (2022) GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. *Nature*. 603: 934–941.  
<https://doi.org/10.1038/s41586-022-04489-4>

Song, H. *et al.* (2022) Scaling up and scaling out: Advances and challenges in manufacturing engineered T cell therapies. *Int. Rev. Immunol.* 41: 638–648.  
<https://doi.org/10.1080/08830185.2022.2067154>

Wang, X. *et al.* (2022) Large-scale manufacturing and characterization of CMV-CD19CAR T cells. *J. Immunother. Cancer* 10: e003461.  
<https://doi.org/10.1136/jitc-2021-003461>

Palen, K. *et al.* (2021) Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model? *Cytotherapy* 23: 985–990.  
<https://doi.org/10.1016/j.jcyt.2021.07.015>

Bozza, M. *et al.* (2021) A nonviral, nonintegrating DNA nanovector platform for the safe, rapid, and persistent manufacture of recombinant T cells. *Sci. Adv.* 7: eabf1333.  
<https://doi.org/10.1126/sciadv.abf1333>

Arcangeli, S. *et al.* (2020) Next-generation manufacturing protocols enriching TSCM CAR T cells can overcome disease-specific T cell defects in cancer patients. *Front. Immunol.* 11: 1217.  
<https://doi.org/10.3389/fimmu.2020.01217>

Li, H. *et al.* (2020) Preclinical development and clinical-scale manufacturing of HIV gag-specific, lentivirus-modified CD4 T cells for HIV functional cure. *Mol. Ther. Methods Clin. Dev.* 17: 1048–1060.  
<https://doi.org/10.1016/j.omtm.2020.04.024>

Loff, S. *et al.* (2020) Rapidly switchable universal CAR-T cells for treatment of CD123-positive leukemia. *Mol. Ther. Oncolytics* 17: 408–420.  
<https://doi.org/10.1016/j.omto.2020.04.009>

Ran, T. *et al.* (2020) Cost of decentralized CAR T-cell production in an academic nonprofit setting. *Int. J. Cancer* 147: 3438–3445.  
<https://doi.org/10.1002/ijc.33156>

Aleksandrova, K. *et al.* (2019) Functionality and cell senescence of CD4/CD8-selected CD20 CAR T cells manufactured using the automated CliniMACS Prodigy Platform. *Transfus. Med. Hemother.* 46: 47–54.  
<https://doi.org/10.1159/000495772>

Fernandez, L. *et al.* (2019) GMP-compliant manufacturing of NKG2D CAR memory T cells using CliniMACS Prodigy. *Front. Immunol.* 10: 2361.  
<https://doi.org/10.3389/fimmu.2019.02361>

Vedvyas, Y. *et al.* (2019) Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy. *Sci. Rep.* 9: 10634.  
<https://doi.org/10.1038/s41598-019-46938-7>

Blaeschke, F. *et al.* (2018) Induction of a central memory and stem cell memory phenotype in functionally active CD4<sup>+</sup> and CD8<sup>+</sup> CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19<sup>+</sup> acute lymphoblastic leukemia. *Cancer Immunol. Immunother.* 67: 1053–1066.  
<https://doi.org/10.1007/s00262-018-2155-7>

Castella, M. *et al.* (2018) Development of a novel anti-CD19 chimeric antigen receptor: A paradigm for an affordable CAR T cell production at academic institutions. *Mol. Ther. Methods Clin. Dev.* 12: 134–144.  
<https://doi.org/10.1016/j.omtm.2018.11.010>

Zhang, W. *et al.* (2018) Characterization of clinical grade CD19 chimeric antigen receptor T cells produced using automated CliniMACS Prodigy system. *Drug Des. Devel. Ther.* 12: 3343–3356.  
<https://doi.org/10.2147/DDDT.S175113>

Zhu, F. *et al.* (2018) Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center. *Cytotherapy* 20: 394–406.  
<https://doi.org/10.1016/j.jcyt.2017.09.005>

Lock, D. & Mockel-Tenbrinck, N. *et al.* (2017) Automated manufacturing of potent CD20-directed chimeric antigen receptor T cells for clinical use. *Hum. Gene Ther.* 28: 914–925.  
<https://doi.org/10.1089/hum.2017.111>

Mock, U. *et al.* (2016) Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS Prodigy. *Cytotherapy* 18: 1002–1011.  
<https://doi.org/10.1016/j.jcyt.2016.05.009>

Priesner, C. *et al.* (2016) Automated enrichment, transduction and expansion of clinical-scale CD62L<sup>+</sup> T cells for manufacturing of GTMPs. *Hum. Gene Ther.* 27: 860–869.  
<https://doi.org/10.1089/hum.2016.091>

**Miltenyi Biotec B.V. & Co. KG** | Friedrich-Ebert-Straße 68 | 51429 Bergisch Gladbach | Germany | Phone +49 2204 8306-0 | Fax +49 2204 85197  
macsde@miltenyi.com | [www.miltenyibiotec.com](http://www.miltenyibiotec.com)

Miltenyi Biotec provides products and services worldwide. Visit [www.miltenyibiotec.com/local](http://www.miltenyibiotec.com/local) to find your nearest Miltenyi Biotec contact.

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. MACS® GMP Products are for research use and *ex vivo* cell culture processing only, and are not intended for human *in vivo* applications. For regulatory status in the USA, please contact your local representative. MACS GMP Products are manufactured and tested under a quality system certified to ISO 13485 and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials. The CliniMACS System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are designed, manufactured and tested under a quality system certified to ISO 13485.

In the EU, the CliniMACS System components are available as CE-marked medical devices for their respective intended use, unless otherwise stated. The CliniMACS Reagents and Biotin Conjugates are intended for *in vitro* use only and are not designated for therapeutic use or direct infusion into patients. The CliniMACS Reagents in combination with the CliniMACS System are intended to separate human cells. Miltenyi Biotec as the manufacturer of the CliniMACS System does not give any recommendations regarding the use of separated cells for therapeutic purposes and does not make any claims regarding a clinical benefit. For the manufacturing and use of target cells in humans, the national legislation and regulations – e.g. for the EU the Directive 2004/23/EC ("human tissues and cells"), or the Directive 2002/98/EC ("human blood and blood components") – must be followed. Thus, any clinical application of the target cells is exclusively within the responsibility of the user of a CliniMACS System.

In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Sets TS and LS, and the CliniMACS PBS/EDTA Buffer, is FDA approved as a Humanitarian Use Device (HUD), authorized by U.S. Federal law for use in the treatment of patients with acute myeloid leukemia (AML) in first complete remission. The effectiveness of the device for this indication has not been demonstrated. Other products of the CliniMACS Product Line are available for use only under an approved Investigational New Drug (IND) application, Investigational Device Exemption (IDE) or FDA approval.

CliniMACS GMP MicroBeads are for research use and *ex vivo* cell processing only. CliniMACS MicroBeads are for research use only and not for human therapeutic or diagnostic use. CliniMACS, CliniMACS Prodigy, MACSQuant, and the Miltenyi Biotec logo are registered trademarks or trademarks of Miltenyi Biotec B.V. & Co. KG and/or its affiliates in various countries worldwide. Copyright © 2023 Miltenyi Biotec and/or its affiliates. All rights reserved.